非布索坦治疗痛风合并高尿酸血症50例  

Febuxostat for Treating Patients with Gout and Hyperuricemia in 50 Cases

作　　者：邹国盛[1] 黄志祥[1] 

机构地区：[1]广东省第二人民医院,广东广州510317

出　　处：《中国药业》2015年第17期111-112,共2页China Pharmaceuticals

摘　　要：目的探讨非布索坦治疗痛风合并高尿酸血症患者的疗效。方法将痛风合并高尿酸血症患者150例分为A1组、A2组和B组,各50例。A1组服用40 mg/d非布索坦片,A2组服用80 mg/d非布索坦片,B组服用300 mg/d别嘌呤醇片,治疗时间均为24周。结果与治疗前相比,治疗10,24周后,3组患者血尿酸水平均显著降低(P<0.05),与B组患者相比,A1组和A2组患者的血尿酸水平均显著降低(P<0.05);与A1组患者相比,A2组患者的血尿酸水平降低不显著(P>0.05)。3组患者的不良反应无明显差异(P>0.05)。结论非布索坦能有效降低痛风患者的血尿酸水平,80 mg/d剂量组血尿酸水平降低效果最好。Objective To investigate the effect of febuxostat in treating Patients with gout combined with hyPeruricemia. Methods 150 Patients with gout and hyPeruricemia were selected and divided into grouP A1,grouP A2 and grouP B, 50 cases in each grouP. GrouP A1 took 40 mg/d of febuxostat tablets,grouP A2 took 80 mg/d of febuxostat tablets,grouP B took 300 mg/d alloPurinol tablets;all Patients were treated for 24 weeks. Results ComPared with before treatment,after treatment for 10,24 weeks,the serum uric acid levels of the three grouPs were significantly decreased（ P 〈 0. 05）. After treatment for 10,24 weeks,comPared with the Patients in grouP B, the serum uric acid level of Patients in A1 and A2 grouP were significantly decreased （ P 〈 0. 05）;comPared with the Patients in grouP A1,the serum uric acid level of Patients in grouP A2 were not decreased significantly （ P 〉 0. 05 ）. There were no significant difference between the three grouPs in adverse reactions （ P 〉 0. 05）. Conclusion Febuxostat can effectively reduce the serum uric acid level in Patients with gout,and the uric acid level of Patients in the 80 mg/d febuxostat grouP were decreased best.

关 键 词：非布索坦 痛风 高尿酸 

分 类 号：R969.4[医药卫生—药理学] R983[医药卫生—药学]